Please use this identifier to cite or link to this item: 10.1016/j.healun.2020.09.011
Title: Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry
Authors: Hoeper, Marius M.
Pausch, Christine
Grünig, Ekkehard
Klose, Hans
Staehler, Gerd
Huscher, Doerte
Pittrow, David
Olsson, Karen M.
Vizza, Carmine Dario
Gall, Henning
Benjamin, Nicola
Distler, Oliver
Opitz, Christian
Gibbs, J. Simon R.
Delcroix, Marion
Ghofrani, H. Ardeschir
Rosenkranz, Stephan
Ewert, Ralf
Kaemmerer, Harald
Lange, Tobias J.
Kabitz, Hans Joachim
Skowasch, Dirk
Skride, Andris
Jureviciene, Elena
Paleviciute, Egle
Miliauskas, Skaidrius
Claussen, Martin
Behr, Juergen
Milger, Katrin
Halank, Michael
Wilkens, Heinrike
Wirtz, Hubert
Pfeuffer-Jovic, Elena
Harbaum, Lars
Scholtz, Werner
Dumitrescu, Daniel
Bruch, Leonhard
Coghlan, Gerry
Neurohr, Claus
Tsangaris, Iraklis
Gorenflo, Matthias
Scelsi, Laura
Vonk-Noordegraaf, Anton
Ulrich, Silvia
Held, Matthias
Rīga Stradiņš University
Keywords: cluster;mortality;phenotypes;pulmonary arterial hypertension;survival;3.2 Clinical medicine;1.1. Scientific article indexed in Web of Science and/or Scopus database;Surgery;Pulmonary and Respiratory Medicine;Cardiology and Cardiovascular Medicine;Transplantation;SDG 3 - Good Health and Well-being
Issue Date: Dec-2020
Citation: Hoeper , M M , Pausch , C , Grünig , E , Klose , H , Staehler , G , Huscher , D , Pittrow , D , Olsson , K M , Vizza , C D , Gall , H , Benjamin , N , Distler , O , Opitz , C , Gibbs , J S R , Delcroix , M , Ghofrani , H A , Rosenkranz , S , Ewert , R , Kaemmerer , H , Lange , T J , Kabitz , H J , Skowasch , D , Skride , A , Jureviciene , E , Paleviciute , E , Miliauskas , S , Claussen , M , Behr , J , Milger , K , Halank , M , Wilkens , H , Wirtz , H , Pfeuffer-Jovic , E , Harbaum , L , Scholtz , W , Dumitrescu , D , Bruch , L , Coghlan , G , Neurohr , C , Tsangaris , I , Gorenflo , M , Scelsi , L , Vonk-Noordegraaf , A , Ulrich , S & Held , M 2020 , ' Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry ' , Journal of Heart and Lung Transplantation , vol. 39 , no. 12 , pp. 1435-1444 . https://doi.org/10.1016/j.healun.2020.09.011
Abstract: The term idiopathic pulmonary arterial hypertension (IPAH) is used to categorize patients with pre-capillary pulmonary hypertension of unknown origin. There is considerable variability in the clinical presentation of these patients. Using data from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension, we performed a cluster analysis of 841 patients with IPAH based on age, sex, diffusion capacity of the lung for carbon monoxide (DLCO; <45% vs ≥45% predicted), smoking status, and presence of comorbidities (obesity, hypertension, coronary heart disease, and diabetes mellitus). A hierarchical agglomerative clustering algorithm was performed using Ward's minimum variance method. The clusters were analyzed in terms of baseline characteristics; survival; and response to pulmonary arterial hypertension (PAH) therapy, expressed as changes from baseline to follow-up in functional class, 6-minute walking distance, cardiac biomarkers, and risk. Three clusters were identified: Cluster 1 (n = 106; 12.6%): median age 45 years, 76% females, no comorbidities, mostly never smokers, DLCO ≥45%; Cluster 2 (n = 301; 35.8%): median age 75 years, 98% females, frequent comorbidities, no smoking history, DLCO mostly ≥45%; and Cluster 3 (n = 434; 51.6%): median age 72 years, 72% males, frequent comorbidities, history of smoking, and low DLCO. Patients in Cluster 1 had a better response to PAH treatment than patients in the 2 other clusters. Survival over 5 years was 84.6% in Cluster 1, 59.2% in Cluster 2, and 42.2% in Cluster 3 (unadjusted p < 0.001 for comparison between all groups). The population of patients diagnosed with IPAH is heterogenous. This cluster analysis identified distinct phenotypes, which differed in clinical presentation, response to therapy, and survival.
Description: Funding Information: Marius M. Hoeper has received fees for lectures and/or consultations from Acceleron, Actelion, Bayer, MSD, and Pfizer. Nicola Benjamin has received fees for lectures and/or consultations from Actelion. Ekkehard Grünig has received fees for lectures and/or consultations from Actelion, Bayer, GSK, MSD, United Therapeutics, and Pfizer. Karen M. Olsson has received fees for lectures and/or consultations from Actelion, Bayer, United Therapeutics, GSK, and Pfizer. C. Dario Vizza has received fees from Actelion, Bayer, GSK, MSD, Pfizer, and United Therapeutics Europe. Anton Vonk-Noordegraaf has received fees for lectures and/or consultation from Actelion, Bayer, GSK, and MSD. Oliver Distler has/had a consultancy relationship with and/or has received research funding from 4-D Science, Actelion, Active Biotec, Bayer, Biogen Idec, Boehringer Ingelheim Pharma, BMS, ChemoAb, EpiPharm, Ergonex, espeRare foundation, GSK, Genentech/Roche, Inventiva, Lilly, medac, MedImmune, Mitsubishi Tanabe, Pharmacyclics, Pfizer, Sanofi, Serodapharm, and Sinoxa in the area of potential treatments of scleroderma and its complications including pulmonary arterial hypertension. In addition, Prof Distler has a patent for mir-29 for the treatment of systemic sclerosis licensed. Christian Opitz has received fees from Actelion, Bayer, GSK, Pfizer, and Novartis. J. Simon R. Gibbs has received fees for lectures and/or consultations from Actelion, Bayer, Bellerophon, GSK, MSD, and Pfizer. Marion Delcroix has received fees from Actelion, Bayer, GSK, and MSD. H. Ardeschir Ghofrani has received fees from Actelion, Bayer, Gilead, GSK, MSD, Pfizer, and United Therapeutics. Doerte Huscher has received fees for lectures and consultations from Actelion. David Pittrow has received fees for consultations from Actelion, Biogen, Aspen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, and Sanofi. Stephan Rosenkranz has received fees for lectures and/or consultations from Actelion, Bayer, GSK, Pfizer, Novartis, Gilead, MSD, and United Therapeutics. Martin Claussen reports honoraria for lectures from Boehringer Ingelheim Pharma GmbH and Roche Pharma and for serving on advisory boards from Boehringer Ingelheim, outside the submitted work. Heinrike Wilkens reports personal fees from Boehringer and Roche during the conduct of the study and personal fees from Bayer, Biotest, Actelion, GSK, and Pfizer outside the submitted work. Juergen Behr received grants from Boehringer Ingelheim and personal fees for consultation or lectures from Actelion, Bayer, Boehringer Ingelheim, and Roche. Hubert Wirtz reports personal fees from Boehringer Ingelheim and Roche outside the submitted work. Hening Gall reports personal fees from Actelion, AstraZeneca, Bayer, BMS, GSK, Janssen-Cilag, Lilly, MSD, Novartis, OMT, Pfizer, and United Therapeutics outside the submitted work. Elena Pfeuffer-Jovic reports personal fees from Actelion, Boehringer Ingelheim, Novartis, and OMT outside the submitted work. Laura Scelsi reports personal fees from Actelion, Bayer, and MSD outside the submitted work. Siliva Ulrich reports grants from Swiss National Science Foundation, Zurich Lung, Swiss Lung, and Orpha Swiss, and grants and personal fees from Actelion SA/Johnson & Johnson Switzerland and MSD Switzerland outside the submitted work. The remaining authors have no conflicts of interest to disclose. Funding Information: This work was supported by the German Centre of Lung Research (DZL). COMPERA is funded by unrestricted grants from Acceleron , Actelion Pharmaceuticals , Bayer , OMT , and GSK . These companies were not involved in data analysis or the writing of this manuscript. Publisher Copyright: © 2020 The Authors Copyright: Copyright 2020 Elsevier B.V., All rights reserved.
DOI: 10.1016/j.healun.2020.09.011
ISSN: 1053-2498
Appears in Collections:Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure

Files in This Item:


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.